报价延迟最少15分钟:2026/09/19 04:14 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
11.02 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.98/-1.80
|
|
企业价值
396.53M
|
| 资产负债 |
|
每股账面净值
5.07
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
0.00
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or haveno effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders. |
